NewsBenzinga일라이 릴리, 파운다요가 ATTAIN-OSA 임상시험에서 52주차에 무호흡-저호흡 지수 감소를 위한 1차 평가변수 충족 발표···수면무호흡증 특이적 저산소성 부담 최대 평균 55.9% 감소 일라이 릴리, 파운다요가 ATTAIN-OSA 임상시험에서 52주차에 무호흡-저호흡 지수 감소를 위한 1차 평가변수 충족 발표···수면무호흡증 특이적 저산소성 부담 최대 평균 55.9% 감소 Benzinga 2026.11.09 14:33 (GMT+0) Open on Benzinga Other news StoneX Maintains Buy on Rivian Automotive, Lowers Price Target to $20 Amer Sports Unleashes $1 Billion Buyback, Raises 2026 Outlook EXCLUSIVE: Tesla Still Rules Leveraged ETFs, but Anthropic IPO and Micron’s Rise Signal What’s Next StoneX Reiterates Hold on iQIYIto Hold StoneX Maintains Buy on Baidu, Lowers Price Target to $125 Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide
Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide